Company intelligence

FORE Biotherapeutics

BiotechSee connections →

Is this your company? Get featured or correct your listing →

Suggest a correction

Recent changes

  1. Jul 7, 2026Raised $67.4M Series D-2 BusinessWire
  2. Jul 7, 2026New investor: SR One Capital Management BusinessWire
  3. Jul 7, 2026FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Jul 7, 2026Series D-2$67.4M—
SR One Capital ManagementLeadunverifiedMedicxiSymBiosis
Pulse story

Investors

SR One Capital Management

Latest Pulse

  1. FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer DrugFORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.→

Coverage Timeline

newest first
  1. Jul 7, 2026FUNDINGFORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug$67.4M (Series D-2 extension)→

All Coverage

FUNDING

FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug

Illustration for: FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug
FUNDING$67.4M (Series D-2 extension)

FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug

FORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly

FORE Biotherapeutics FAQ

Who are FORE Biotherapeutics's investors?

FORE Biotherapeutics's investors include SR One Capital Management.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction